Industry

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. Novosteo stockholders now own … [Read more…]

Development of Exodus Algorithm Overcomes Limitations in Identifying and Quantifying the Genomes of Genetically Related Microorganisms BRANFORD, Conn. & NESS ZIONA, Israel–(BUSINESS WIRE)–BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the publication of a scientific paper … [Read more…]

– Business combination transaction with OTR Acquisition Corp., a special purpose acquisition company, completed – – Combined company Comera Life Sciences Holdings, Inc. will be listed on the Nasdaq Capital Market under ticker symbol “CMRA” – WOBURN, Mass.–(BUSINESS WIRE)–Comera Life Sciences Holdings, Inc. (“Comera” or the “Company”), which is developing a new generation of bio-innovative … [Read more…]

Modern Healthcare Ranks Trella Health on Best Places to Work List ATLANTA–(BUSINESS WIRE)–Trella Health, a leading source of healthcare growth insights and performance analytics, has been selected by Modern Healthcare as one of the 2022 Best Places to Work in Healthcare, sponsored by Healthcare Plus Solutions Group. The complete list of this year’s winners, in … [Read more…]

 Research to Prevent Blindness and Castle Biosciences are partnering to provide new opportunities for medical students to pursue ocular cancer research   NEW YORK & FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Research to Prevent Blindness (RPB) and Castle Biosciences today announced that they are partnering to increase opportunities for medical students to gain research experiences, specifically in the … [Read more…]

With pioneering digital technology from KLOwen, patients seeking the perfect smile no longer have to endure the typical 27 months and 19 office visits associated with traditional braces. Such prolonged treatment regimens are quickly becoming a relic of the past, as custom braces have been shown to achieve superior results in 20-40% less time. This … [Read more…]

BAUDETTE, Minn.–(BUSINESS WIRE)–ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at two upcoming conferences as follows: H.C. Wainwright Global Investment Conference (Virtual)     Date: Tuesday, May 24, 2022     Time: On Demand, 7:00 a.m. ET   … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global RNA Based Therapeutic Market By Type, By Application, By End User, By Regional Outlook, Industry Analysis Report and Forecast, 2021-2027” report has been added to ResearchAndMarkets.com’s offering. The Global RNA Based Therapeutic Market size is expected to reach $11.4 billion by 2027, rising at a market growth of 15.1 % CAGR during … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Osteoporosis Therapeutics – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. The global market for Osteoporosis Therapeutics estimated at US$11.5 Billion in the year 2020, is projected to reach a revised size of US$14 Billion by 2027, growing at a CAGR of 2.8% over the analysis period 2020-2027. Bisphosphonates, … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Proliferative Vitreoretinopathy (PVR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. The pipeline guide provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape. It provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy, complete with … [Read more…]